About the experts
Dr. Stephen Pereira
Dr. Stephen Pereira is Professor of Hepatology & Gastroenterology at University College London since October 2016. He has been a Senior Lecturer then Reader from 2003 and a Consultant Gastroenterologist in PancreaticoBiliary Medicine at University College London Hospitals from 2000. He undertook undergraduate studies in science (theoretical physics) and medicine at University of New South Wales, Sydney, with postgraduate training mainly at Guy s and King s College Hospital, London, and advanced endoscopy training (ERCP and endoscopic ultrasound) in Paris, Amsterdam and Indianapolis. Over the last several years he has developed a clinical research programme aimed at improving the diagnosis and treatment of patients with liver and pancreaticobiliary malignancy and lead a clinical and laboratory-based research group based at the Royal Free Campus. Dr. Stephen Pereira s research areas include Cancer Proteomics, Cancer Biomarker Discovery
Norway
United-states
Paris
France-general
France
United-kingdom
Newton-wellesley-hospital
Massachusetts
Boston
London
City-of
Amsterdam
Jan 15 2021 Read 639 Times
A license agreement with two Netherlands Institutes enabling development of a novel clinical laboratory test for minimal residual disease (MRD) status directly on serum samples of multiple myeloma patients has been announced by French company Sebia.
The partnership with Erasmus University Medical Center in Rotterdam and the Radboud University Medical Center in Nijmegen, aims to offer a more accessible and sensitive MRD test based on serum-protein electrophoresis (SPE), immunofixation and free light chains. These techniques are recommended by the International Myeloma Working Group (IMWG). The specific terms of the agreement have not been disclosed.
“Very high sensitivity MRD assessment in blood will revolutionise patients’ myeloma management and speed up therapeutic innovations. This unique personalised targeted mass spectrometry technology brings unprecedented clinical value in fighting myeloma,” said Pierre Sonigo, chief scientific officer at Se
Netherlands
France
Nijmegen
Gelderland
French
Dutch
Pierre-sonigo
Shans-jacobs
Radboud-university-medical-center
International-myeloma-working-group
Department-of-neurology
Erasmus-university-medical-center